BPC 157 + TB 500
The ultimate regenerative stack combining BPC-157 and TB-500 (Thymosin Beta-4 fragment). Widely studied for synergistic healing, tissue repair, and recovery applications.
Compound Profile
Pharmaceutical Data Sheet
Mechanism of Action
How BPC 157 + TB 500 Works
This combination pairs two of the most researched regenerative peptides through complementary mechanisms: BPC-157 drives vascular repair and growth factor signaling (VEGFR2, eNOS), while TB-500 (thymosin beta-4 fragment) promotes actin-based cell migration and anti-fibrotic tissue remodeling. Together they address both the vascular supply and the cellular repair phases of healing.
- VEGFR2 upregulation and eNOS activation
- New capillary formation at injury sites
- Growth factor cascade (EGF, FGF, PDGF)
- G-actin sequestration promotes F-actin polymerization
- Accelerates fibroblast and satellite cell migration
- Anti-fibrotic β modulates scar tissue formation
- BPC-157 builds the vascular supply
- TB-500 migrates repair cells into position
- Complementary timing: inflammation β vascularization β repair
BPC-157 creates the vascular infrastructure (new capillaries, improved perfusion) while TB-500 enables cells to migrate into the repair zone via actin polymerization. This vascular + cellular synergy is why the combination is widely used in musculoskeletal recovery research.
Based on individually published BPC-157 and thymosin Ξ²4 mechanisms.
Preclinical Findings
Research Models
Clinical Data
Combined Regenerative Research
BPC-157 and TB-500 are individually among the most published regenerative peptides. Their combination targets complementary repair phases β vascular remodeling (BPC-157) and cell migration/anti-fibrosis (TB-500).
Individual component publications β see BPC-157 research page.
Preclinical data for individual components
Research Outcomes
Key Research Success Metrics
Safety Profile
Research Safety Notes
- BPC-157: No LD50 established β exceptional safety ceiling in all animal models
- TB-500: No significant adverse events in preclinical wound and cardiac studies
- No known drug interactions between the two peptides
- Both are body-protective/endogenous-derived sequences
- Well-tolerated across subcutaneous and intramuscular routes
This combination stack pairs two preclinical peptides. Synergistic effects not studied in clinical trials. For research use only.
About BPC 157 + TB 500
The ultimate regenerative stack combining BPC-157 and TB-500 (Thymosin Beta-4 fragment). Widely studied for synergistic healing, tissue repair, and recovery applications.
All EVO Labs Research compounds are manufactured to research-grade standards and independently tested by Janoshik Analytical (Prague, est. 2013). The Certificate of Analysis for this compound includes full HPLC chromatography data, mass spectrometry confirmation, net purity percentage, and net content verification.
Research Use Only
This product is strictly for in vitro research and laboratory use only. Not for human or veterinary consumption. By purchasing, you confirm use in a controlled research setting.
